

Royal College of Paediatrics and Child Health

50 Hallam Street, London W1W 6DN

Fax:

Tel:

E-mail: enquiries@rcpch.ac.uk

<u>RCPCH Response to the Appraisal Consultation Document for the NICE Technology</u> <u>Appraisal 'Pregnancy – Anti – D for Rhesus Negative Women'</u>

Thank you for inviting the RCPCH to consult on the draft version of the above appraisal consultation document. Please find below some comments on the document.

General

The College believes that this document addresses the question of efficacy and cost effectiveness and has reached a clear conclusion. The introduction regarding the process of sensitization and the hazards to the baby have been written in very simple English and yet the description of the economic modelling provides no comparable explanation. The College is puzzled that the ICER is defined as a ratio and yet appeared to be presented in units of £. It would be helpful to include perhaps a simple table with on one side the cost of prophylaxis and the cost of care of sensitised pregnancies and affected babies, compared with the costs of the obstetric & neonatal/paediatric care if no prophylaxis is undertaken. This could be presented per 1000 deliveries so that individual PCTs could use it to calculate costs and savings when adopting the policy.

The College will be interested to see the supporting information when the policy is launched.

4.3.9

The College believes that 4.3.9 is unworkable in practice, and as such may continue to leave a group of women unprotected. While clearly fully informed consent is required before immunisation can be offered, the fact that the woman is for instance in a "stable" relationship with a RhD negative partner at that time should not be a contraindication to receiving this immunisation.

With Thanks to: